Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/11287972/

A Phase 2 Study of Imatinib in Patients With Relapsed or Refractory Philadelphia Chromosome-positive Acute Lymphoid Leukemias https://pubmed.ncbi.nlm.nih.gov/12200353/

International CML Foundation https://www.cml-foundation.org/

Resistance to Imatinib: Mechanisms and Management https://pubmed.ncbi.nlm.nih.gov/16316612/

Ponatinib Dose-ranging Study in Chronic-phase Chronic Myeloid Leukemia: A Randomized, Open-label Phase 2 Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34407543/

Asciminib Monotherapy in Patients With CML-CP Without BCR::ABL1 T315I Mutations Treated With at Least Two Prior TKIs: 4-year Phase 1 Safety and Efficacy Results https://pubmed.ncbi.nlm.nih.gov/36949155/

Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib https://pubmed.ncbi.nlm.nih.gov/32470534/

A Kinase Inhibitor Which Specifically Targets the ABL Myristate Pocket (STAMP), but Unlike Asciminib Crosses the Blood-brain Barrier https://pubmed.ncbi.nlm.nih.gov/35065232/

Olverembatinib (HQP1351), a Well-tolerated and Effective Tyrosine Kinase Inhibitor for Patients With T315I-mutated Chronic Myeloid Leukemia: Results of an Open-label, Multicenter Phase 1/2 Trial https://pubmed.ncbi.nlm.nih.gov/35982483/